The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: a pathophysiological update
MA Nauck, DR Quast, J Wefers… - Diabetes, Obesity and …, 2021 - Wiley Online Library
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials
T Min, SC Bain - Diabetes Therapy, 2021 - Springer
Abstract Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option
for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the …
for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the …
Incretin hormones: Their role in health and disease
MA Nauck, JJ Meier - Diabetes, Obesity and Metabolism, 2018 - Wiley Online Library
Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …
Incretin hormones and type 2 diabetes
abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …
Glucagon-like peptide 1 in health and disease
In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …
Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB
The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …
management of obesity and type 2 diabetes mellitus and novel developments in …
GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials
MP Gilbert, RE Pratley - Frontiers in endocrinology, 2020 - frontiersin.org
The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
MA Nauck, JJ Meier - The lancet Diabetes & endocrinology, 2016 - thelancet.com
The incretin effect describes the phenomenon whereby oral glucose elicits higher insulin
secretory responses than does intravenous glucose, despite inducing similar levels of …
secretory responses than does intravenous glucose, despite inducing similar levels of …